Business Development

Challenge Our client was a privately-held US biotech company developing a proprietary platform technology for in vivo expression of DNA coding for a therapeutic antibody or protein. The approach...

Challenge: Our client, a PE-backed specialty pharma company growing rapidly through M&A, was assessing a number of late-stage development projects to license/acquire. The asset in question was a...

Challenge One of the leading medical imaging companies worldwide approached Alacrita to assess an opportunity to acquire the manufacturing and distribution rights to an important imaging agent used...

Challenge Our client, a UK-based private equity company, was evaluating an investment in a full service global medical communications agency with a portfolio of blue-chip biopharma clients, and as...

Challenge: A pharma company was interested in identifying novel protein-based autoimmune / auto-inflammatory assets early in development from pre-GLP studies to 18 months from an IND. The company had...

Challenge: A phase 2 clinical-stage pharma company intent on supplementing their internal pipeline with external innovation asked Alacrita to identify immune-oncology or vaccine assets owned by...

Challenge: A new venture fund reached out to Alacrita for support with identifying novel pharma assets available for in-licensing, for the purpose of founding a new start-up and enabling the further...

Challenge: A disease area unit within a global biopharmaceutical company was charged with a mandate to seek out novel candidate assets in development to treat inflammatory bowel disease (IBD) and...

Project Challenge: Our client was a company on which we had conducted due diligence for an investor approached us for support with a potential deal with an AI discovery company. The concept was to...

Challenge: A venture capital portfolio company developing small molecule therapeutics for metabolic/obesity indications had made the strategic decision to supplement their internal product pipeline...

Challenge Our client, a PE-backed specialty pharma company growing rapidly through M&A, was assessing a number of late-stage development projects to license/acquire. The company was considering a...

Challenge A major VC fund asked Alacrita to conduct a clinical due diligence on a potential investment in a company targeting CNS indications. The target company was led by an executive with whom the...